Citations

Clear

4847 citation(s) found for "Yu, Eric".

Esophageal overtubes provide no benefit to safety or technical success in upper gastrointestinal tract endoscopic suturing
Storm, Andrew C. , Matar, Reem , Song, Louis M. Wong Kee , Sawas, Tarek , Buttar, Navtej , Topazian, Mark , Wong Kee Song, Louis M, Bazerbachi, Fateh , Buttar, Navtej S, Abu Dayyeh, Barham K, Matar, Reem , Storm, Andrew C , Vargas, Eric J. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | July 11, 2019 | Volume: 07 | Issue: 07 | Pages: E919-E921

10.1055/a-0953-2152 | PMID 31304237 Get It

Abstract Background and study aim The role of esophageal overtubes in upper gastrointestinal endoscopic suturing is unknown. This study aimed to determine whether overtube use was associated with technical success or adverse events. Patients and methods A retrospective review of consecutive patients who underwent endoscopic suturing for various indications was performed. Results A total of 719 patients underwent endoscopic suturing for various indications, including endoscopic bariatric procedures in 262, stent fixation in 258, defect closure in 190, and hemostasis in nine. An overtube was used in 186 procedures (25.9 %). Technical success was achieved in all cases. Minor mucosal trauma occurred in 15 cases (8.1 %) with use of an overtube, and none without an overtube (P < 0.0001). No full-thickness esophageal perforation or hemorrhage related to overtube use or the suturing device occurred. Conclusions Endoscopic suturing can be performed safely for a variety of indications, including endoscopic bariatric procedures, defect repair, and stent fixation without an esophageal overtube. Minor esophageal mucosal trauma and equipment cost are increased when an overtube is used.
Cavernous Sinus Thrombosis Secondary to Sphenoid Sinus Fungal Ball
Dowling, Eric M. , Modzeski, Mara C., Dowling, Eric , Modzeski, Mara, Choby, Garret

Mayo Clinic

Ear, Nose & Throat Journal | July 11, 2019 | Volume: 98 | Issue: 9 | Pages: 540-542

10.1177/0145561319862220 | PMID 31291783 Get It

Establishing Normal Values for F-Wave Latencies in Diagnosing Peripheral Neuropathies for the Pediatric Population
Sharma, Rishi , Sorenson, Eric J. , Ryan, Conor S. , Conlee, Erin M., Boon, Andrea J. , Laughlin, Ruple S.

Mayo Clinic

Journal of Clinical Neurophysiology | July 8, 2019 | Volume: 37 | Issue: 1 | Pages: 68-73

10.1097/wnp.0000000000000609 | PMID 31274707 Get It

Purpose: We present a unique technique applying F-wave latencies to assist in the diagnosis of peripheral neuropathy within the pediatric age group. Methods: We calculated an F-wave estimated deviance adjusted for limb length measurements, distal motor conduction velocity, and distal motor latencies. We compared the F-wave estimated deviance from the normal subjects with those with peripheral neuropathy (both axonal and demyelinating) to establish diagnostic accuracy in pediatric patients. Results: The normal range for the F-wave estimated deviance in the upper limb was −1 to +6 ms and in the lower limb was −8 to +5 ms. When compared with 82 subjects with peripheral neuropathy, there was a significant difference between the normal subjects and those with neuropathy (P values between 0.002 and 0.0005 for each of the individual nerves tested). Conclusions: The F-wave estimated deviance is independent of age and can be accurately applied to the electrodiagnostic testing of pediatric patients with suspected neuropathy.
Trends in Direct Hospital Payments to Anesthesia Groups
O’Connell, Chloe, Dexter, Franklin , Mauler, David J. , Sun, Eric

Mayo Clinic

Anesthesiology | July 8, 2019 | Volume: 131 | Issue: 3 | Pages: 534-542

10.1097/aln.0000000000002819 | PMID 31283739 Get It

Abstract Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New Background In addition to payments for services, anesthesia groups in the United States often receive revenue from direct hospital payments. Understanding the magnitude of these payments and their association with the hospitals’ payer mixes has important policy implications. Methods Using a dataset of financial reports from 240 nonacademic California hospitals between 2002 and 2014, the authors characterized the prevalence and magnitude of direct hospital payments to anesthesia groups, and analyzed the association between these payments and the fraction of anesthesia revenue derived from public payers ( e.g. , Medicaid). Results Of hospitals analyzed, 69% (124 of 180) made direct payments to an anesthesia group in 2014, compared to 52% (76 of 147) in 2002; the median payment increased from $242,351 (mean, $578,322; interquartile range, $72,753 to $523,861; all dollar values in 2018 U.S. dollars) to $765,128 (mean, $1,295,369; interquartile range, $267,006 to $1,503,163) during this time period. After adjusting for relevant covariates, hospitals where public insurers accounted for a larger fraction of anesthesia revenues were more likely to make direct payments to anesthesia groups (β = 0.45; 95% CI, 0.10 to 0.81; P = 0.013), so that a 10–percentage point increase in the fraction of anesthesia revenue derived from public payers would be associated with a 4.5–percentage point increase in the probability of receiving any payment. Among hospitals making payments, our results (β = 2.10; 95% CI, 0.74 to 3.45; P = 0.003) suggest that a 1–percentage point increase in the fraction of anesthesia revenue derived from public payers would be associated with a 2% relative increase in the amount paid. Conclusions Direct payments from hospitals are becoming a larger financial consideration for anesthesia groups in California serving nonacademic hospitals, and are larger for groups working at hospitals serving publicly insured patients.
Individualized Delay for Abdominal Computed Tomography Angiography Bolus-Tracking Based on Sequential Monitoring: Increased Aortic Contrast Permits Decreased Injection Rate and Lower Iodine Dose
Gutjahr, Ralf , Lee, Yong S. , Halaweish, Ahmed F., Suresh, Vighnesh , Weber, Nikkole M. , Vrtiska, Terri J., Williamson, Eric E. , Schmidt, Bernhard , Fletcher, Joel G. , McCollough, Cynthia H.

Mayo Clinic

Journal of Computer Assisted Tomography | July 3, 2019 | Volume: 43 | Issue: 4 | Pages: 612-618

10.1097/rct.0000000000000874 | PMID 31268876 Get It

Objective The aim of this study was to determine if computed tomography (CT) angiography using an individualized transition delay (CTA-ID) would facilitate reductions in injection rate and iodine dose. Methods The CTA-ID was performed in 20 patients with routine injection rate and iodine dose; 20 patients with injection rate lowered by 1 mL/s; and 40 patients with injection rate lowered by 1 mL/s with 29% less iodine. Routine CTAs in the same or size-matched patients served as controls. Diagnostic image quality and intra-arterial CT numbers were assessed. Results The median transition delay between aortic threshold and CTA-ID image acquisition was significantly longer than with conventional bolus tracking (mean increase, 13.3 seconds; P < 0.0001), with image quality being the same or better. Intra-arterial CT numbers were 200 Hounsfield units or greater for 80 of 80 CTA-ID, but not for 6 of 49 (12%) internal control or for 11 of 80 (14%) size-matched control patients. Conclusion The CTA-ID bolus-tracking software alters transition delays to permit diagnostic CTA examinations despite slower injection rate and less iodine.
Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition
Wilson, Jessica R. , Kerman, Scott Reza Jafarian , Hubers, Scott , Nian, Hui , Grouzmann, Eric , Eugster, Philippe J. , Mayfield, Dustin, Brown, Nancy J. , Kerman, Scott Jafarian , Hubers, Scott A , Grouzmann, Eric , Eugster, Philippe J , Brown, Nancy J , Yu, Chang

Mayo Clinic

Journal of the Endocrine Society | July 1, 2019 | Volume: 3 | Issue: 10 | Pages: 1784-1798

10.1210/js.2019-00185 | PMID 31528826 Get It

Abstract Context Dipeptidyl peptidase 4 (DPP4) inhibitors may increase the risk of heart failure. Decreased degradation of vasoactive peptides like substance P [also degraded by angiotensin-converting enzyme (ACE)] and Y1 agonists peptide YY (PYY 1-36) and neuropeptide Y (NPY 1-36) could contribute. Objective This study tested the hypothesis that there is an interactive effect of DPP4 inhibition and ACE inhibition (vs antihypertensive control subjects) on vasoactive peptides after a mixed meal. Participants and Design Fifty-three patients with type 2 diabetes and hypertension were randomized to double-blind treatment with ramipril, valsartan, or amlodipine for 15 weeks in parallel groups. During the 5th, 10th, and 15th weeks, participants also received placebo + placebo, sitagliptin 100 mg/d + placebo, and sitagliptin + aprepitant 80 mg/d in random order. On the last day of each crossover treatment, participants underwent a mixed-meal study. Results Sitagliptin increased postprandial glucagon-like peptide-1 and decreased glucose in all antihypertensive groups. Sitagliptin increased NPY 1-36 and decreased Y2 agonists NPY 3-36 and PYY 3-36 in all groups. During ramipril or valsartan, but not amlodipine, sitagliptin increased postprandial norepinephrine; substance P receptor blockade with aprepitant prevented this effect. Despite increased norepinephrine, sitagliptin decreased postprandial blood pressure during ACE inhibition. Conclusion DPP4 inhibition increases postprandial concentrations of the Y1 agonist NPY 1-36. During treatment with an ACE inhibitor or angiotensin receptor blocker, DPP4 inhibition increased postprandial norepinephrine through a substance P receptor–dependent mechanism. Increased NPY 1-36 and norepinephrine could increase risk of heart failure but did not result in higher postprandial blood pressure.
Molecular characterization of known and novel ACVR1 variants in phenotypes of aberrant ossification
Gupta, Aditi , Zimmermann, Michael T. , Sigafoos, Ashley N. , Macklin, Sarah , Pignolo, Robert J. , Klee, Eric W. , Macklin, Sarah K, Urrutia, Raul A, Zimmermann, Michael T , Wang, Haitao , Broski, Stephen M. , Urrutia, Raúl , Clark, Karl J. , Atwal, Paldeep S

Mayo Clinic

American Journal of Medical Genetics Part A | June 26, 2019 | Volume: 179 | Issue: 9 | Pages: 1764-1777

10.1002/ajmg.a.61274 | PMID 31240838 Get It

AbstractDiffuse idiopathic skeletal hyperostosis (DISH) is a disorder principally characterized by calcification and ossification of spinal ligaments and entheses. Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disabling disorder characterized by progressive ossification of skeletal muscle, fascia, tendons, and ligaments. These conditions manifest phenotypic overlap in the ossification of tendons and ligaments. We describe herein a patient with DISH, exhibiting heterotopic ossification of the posterior longitudinal ligament where clinical whole exome sequencing identified a variant within ACVR1, a gene implicated in FOP. This variant, p.K400E, is a novel variant, not identified previously, and occurs in a highly conserved region across orthologs. We used sequence‐based predicative algorithms, molecular modeling, and molecular dynamics simulations, to test the potential for p.K400E to alter the structure and dynamics of ACVR1. We applied the same modeling and simulation methods to established FOP variants, to identify the detailed effects that they have on the ACVR1 protein, as well as to act as positive controls against which the effects of p.K400E could be evaluated. Our in silico molecular analyses support p.K400E as altering the behavior of ACVR1. In addition, functional testing to measure the effect of this variant on BMP‐pSMAD 1/5/8 target genes was carried out which revealed this variant to cause increased ID1 and Msx2 expression compared with the wild‐type receptor. This analysis supports the potential for the variant of uncertain significance to contribute to the patient's phenotype.
A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation
Carey, Elizabeth J. , Lai, Jennifer C. , Sonnenday, Christopher J. , Tapper, Elliot B. , Duarte‐Rojo, Andrés , Dunn, Michael A. , Tsien, Cynthia , Kallwitz, Eric R. , Ng, Vicky L. , Bashir, Mustafa R. , Montano-Loza, Aldo J , Lai, Jennifer , Duarte-Rojo, Andres , Tandon, Puneeta , Dasarathy, Srinivasan , Kappus, Matthew R. , Montaño‐Loza, Aldo J.

Mayo Clinic

Hepatology | June 20, 2019 | Volume: 70 | Issue: 5 | Pages: 1816-1829

10.1002/hep.30828 | PMID 31220351 Get It

Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse outcomes in this population, including poor quality of life, hepatic decompensation, mortality in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensive care unit stay, higher incidence of infection following LT, and higher overall health care cost. Although it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, including the best modality for assessing muscle mass, the optimal cut‐off values for sarcopenia, the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical decision making. For these reasons, we assembled a group of experts to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. Skeletal muscle index (SMI) assessed by computed tomography constitutes the best‐studied technique for assessing sarcopenia in patients with cirrhosis. Cut‐off values for sarcopenia, defined as SMI < 50 cm 2 /m 2 in male and < 39 cm 2 /m 2 in female patients, constitute the validated definition for sarcopenia in patients with cirrhosis. Conclusion: The management of sarcopenia requires a multipronged approach including nutrition, exercise, and additional pharmacological therapy as deemed necessary. Future studies should evaluate whether recovery of sarcopenia with nutritional management in combination with an exercise program is sustainable as well as how improvement in muscle mass might be associated with improvement in clinical outcomes.
Coexistence of Progressive Supranuclear Palsy With Pontocerebellar Atrophy and Myotonic Dystrophy Type 1
Koga, Shunsuke , Ahlskog, J. Eric , DeTure, Michael , Baker, Matt , Roemer, Shanu F. , Rademakers, Rosa , Ross, Owen A. , Dickson, Dennis W. , DeTure, Michael A, Dickson, Dennis W , Koga, Shunsuke , Ross, Owen A , Konno, Takuya

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | June 19, 2019 | Volume: 78 | Issue: 8 | Pages: 756-762

10.1093/jnen/nlz048 | PMID 31216016 Get It

AbstractProgressive supranuclear palsy with predominant cerebellar ataxia (PSP-C) has been reported as a rare clinical subtype, but the underlying pathology of its cerebellar ataxia remains unclear. Here, we report a patient with the coexistence of PSP with pontocerebellar atrophy and myotonic dystrophy type 1 (DM1). A 73-year-old man who was an asymptomatic carrier of DM1 (66 CTG repeats) started developing ataxic gait with multiple falls, visual blurring, double vision, and word finding difficulty at age 62 and was initially diagnosed with multiple system atrophy (MSA). Subsequently, the diagnosis was changed to PSP due to hypometric downward gaze, reduced blink frequency, symmetric bradykinesia, rigidity, and the absence of autonomic dysfunction. He eventually developed delayed grip opening with percussion myotonia at age 72. At autopsy, severe neuronal degeneration and astrogliosis in the pontocerebellar structures suggested MSA, but immunohistochemistry for α-synuclein did not reveal neuronal or glial cytoplasmic inclusions. Immunohistochemistry for phospho-tau and 4-repeat tau confirmed a neuropathological diagnosis of PSP with exceptionally numerous coiled bodies and threads in the pontine base and cerebellar white matter. This unusual distribution of 4-repeat tau pathology and neuronal degeneration with astrogliosis is a plausible clinicopathological substrate of PSP-C.